Antibe Therapeutics Inc (CVE:ATE), a commercial-stage healthcare company, alerted investors Tuesday about a new research article in the British Journal of Pharmacology regarding the successful 2B GI safety trial for its lead drug ATB-346.
ATB-346 is a hydrogen sulfide-releasing derivative of naproxen, a non-steroid anti-inflammatory drug that is used to relieve pain from various conditions.
READ: British Journal of Pharmacology research article
Non-steroidal anti-inflammatory drugs such as naproxen are common pain therapies for osteoarthritis and gout, but their use is associated with a high incidence of gastrointestinal ulceration and bleeding.
The results of the safety study published in the British Journal of Pharmacology provide evidence that ATB-346 is less toxic, but as effective as naproxen in alleviating pain, according to John Wallace, Antibe’s chief scientific officer.
“We are pleased that the results of our Phase 2B GI safety study for ATB-346 have been published in BJP,” Wallace said in a statement. “The results provide unequivocal evidence for a dramatic reduction of GI toxicity of ATB‐346 as compared to naproxen, with equivalent suppression of the enzyme (cyclooxygenase; COX) that produces substances that cause pain.”
Headquartered in Toronto, Antibe develops non-addictive medicines for pain and inflammation.
Contact Ellen Kelleher at [email protected]
